May 20 2010
Elixir Medical Corporation, a developer of innovative drug eluting stent platforms for the treatment of cardiovascular disease, today announced two key presentations scheduled for the 2010 EuroPCR meeting featuring the company's cardiovascular innovations.
“Myolimus Eluting Coronary Stent System with a Bioabsorbable Polymer: Twelve-Month Clinical and Angiographic Results.”
Nine-month clinical, angiographic and IVUS results from the EXCELLA II Clinical Trial will be presented during the late-breaking clinical trial session. EXCELLA II is a randomized, single blinded study designed to evaluate the long-term safety and efficacy of the Elixir DESyne Novolimus-Eluting Coronary Stent System in 210 patients in Europe, New Zealand, Australia and Brazil. Also featured will be the 12-month clinical, angiographic and IVUS results from the Elixir Myolimus-Eluting Coronary Stent System with Bioabsorbable Polymer first-in-man study. Clinical results will be presented in the following sessions at EuroPCR Paris, France, May 25-28.
Tuesday, May 25
Late Breaking Clinical Trials, Main Arena: 16:31 to 16:43
- "ELIXIR EXCELLA II Randomized Clinical Trial: Nine month clinical safety, angiographic and IVUS results." Presented by Professor Alexandre Abizaid, M.D., PhD. of the Instituto Dante Pazzanese de Cardiologia in Sao Paulo, Brazil.
Friday, May 28
Room 252B: 10:00 to 10:09
- "Myolimus Eluting Coronary Stent System with a Bioabsorbable Polymer: Twelve-Month Clinical and Angiographic Results." Presented by Professor Joachim Schofer, M.D., PhD. of the Hamburg University Cardiovascular Center in Hamburg, Germany.
SOURCE Elixir Medical Corporation
Conch shell blowing lowers apnea events during REM sleep